Home › Research › Drug development
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
A Dei Cas, M M Micheli, R Aldigeri, S Gardini, F Ferrari-Pellegrini, M Perini, G Messa, M Antonini et al.. Journal of endocrinological investigation, 2024-04-02
Topic: Drug trials: efficacy and safety
No significant between-group effects of exenatide on ADAS-Cog11 score (p = 0.17) were detected. A gender interaction with treatment was observed (p = 0.04), due to worsening of the ADAS-Cog11 score in women randomized to exenatide (p = 0.018), after correction for age, scholar level, dysglycemia, and ADAS-Cog score baseline value. Fasting plasma glucose (p = 0.02) and body weight (p = 0.03) decreased in patients randomized to exenatide. In patients with MCI, a 32-week trial with slow-release exenatide had no beneficial effect on cognitive performance. TRIAL REGISTRATION NUMBER: NCT03881371, registered on 21 July, 2016.
Key findings
- No significant between-group effects of exenatide on ADAS-Cog11 score (p = 0.17) were detected.
- A gender interaction with treatment was observed (p = 0.04), due to worsening of the ADAS-Cog11 score in women randomized to exenatide (p = 0.018), after correction for age, scholar level, dysglycemia, and ADAS-Cog score baseline value.
- Fasting plasma glucose (p = 0.02) and body weight (p = 0.03) decreased in patients randomized to exenatide.
- In patients with MCI, a 32-week trial with slow-release exenatide had no beneficial effect on cognitive performance.
- TRIAL REGISTRATION NUMBER: NCT03881371, registered on 21 July, 2016.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants17
- Evidence strengthHigh
How this study scored 79/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 44 of the 56 points we could judge it on, which is 79 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of endocrinological investigation) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 17 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38565814) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 44 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 44 of the 56 points we could judge it on is 79 out of 100. |
| Total | 79 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Cas, A. D., Micheli, M. M., Aldigeri, R., Gardini, S., Ferrari-Pellegrini, F., Perini, M., et al. (2024). Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. Journal of endocrinological investigation. https://doi.org/10.1007/s40618-024-02320-7
Vancouver
Cas AD, Micheli MM, Aldigeri R, Gardini S, Ferrari-Pellegrini F, Perini M, et al. Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. Journal of endocrinological investigation. 2024. doi:10.1007/s40618-024-02320-7. PMID: 38565814.
BibTeX
@article{cas2024-38565814,
author = {Cas, A Dei and Micheli, M M and Aldigeri, R and Gardini, S and Ferrari-Pellegrini, F and Perini, M and Messa, G and Antonini, M and others},
title = {{Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial}},
journal = {Journal of endocrinological investigation},
year = {2024},
doi = {10.1007/s40618-024-02320-7},
pmid = {38565814},
url = {https://doi.org/10.1007/s40618-024-02320-7}
}